Role of dyslipidemia in impairment of energy metabolism, oxidative stress, inflammation and cardiovascular disease in chronic kidney disease

被引:0
|
作者
Nosratola D. Vaziri
机构
[1] University of California Irvine Medical Center,Division of Nephrology and Hypertension
来源
关键词
End-stage renal disease; Oxidative stress; Impaired exercise capacity; Skeletal muscle; Adipose tissue; Lipid metabolism; Malnutrition;
D O I
暂无
中图分类号
学科分类号
摘要
Advanced chronic kidney disease (CKD) results in a constellation of dysregulation of lipid metabolism, oxidative stress, and inflammation which are causally interconnected and participate in a vicious cycle. The CKD-associated lipid disorders are marked by impaired clearance of very low density lipoprotein and chylomicrons, hypertriglyceridemia, formation of small dense low-density lipoprotein (LDL), oxidative modification of LDL, intermediate density lipoprotein and chylomicron remnants, and high-density lipoprotein deficiency and dysfunction. This review provides a brief overview of the role of CKD-induced lipid disorders in the pathogenesis of oxidative stress, inflammation, cardiovascular disease, impaired exercise capacity, cachexia and wasting syndrome.
引用
收藏
页码:265 / 268
页数:3
相关论文
共 50 条
  • [41] Role of altered intestinal microbiota in systemic inflammation and cardiovascular disease in chronic kidney disease
    Mafra, Denise
    Lobo, Julie C.
    Barros, Amanda F.
    Koppe, Laetitia
    Vaziri, Nosratola D.
    Fouque, Denis
    FUTURE MICROBIOLOGY, 2014, 9 (03) : 399 - 410
  • [42] Astaxanthin, oxidative stress, inflammation and cardiovascular disease
    Fassett, Robert G.
    Coombes, Jeff S.
    FUTURE CARDIOLOGY, 2009, 5 (04) : 333 - 342
  • [43] Magnesium, Oxidative Stress, Inflammation, and Cardiovascular Disease
    Liu, Man
    Dudley, Samuel C.
    ANTIOXIDANTS, 2020, 9 (10) : 1 - 31
  • [44] Kidney disease and cardiovascular disease: Implications of dyslipidemia
    Keane, WF
    Lyle, PA
    CARDIOLOGY CLINICS, 2005, 23 (03) : 363 - +
  • [45] The effects of chronic kidney disease stages on dyslipidemia, cardiovascular disease prevalence and mortality
    Hoca, Emre
    Mermer, Huseyin Bulent
    Kula, Atay Can
    Ahbab, Suleyman
    Ataoglu, Hayriye Esra
    NORTHERN CLINICS OF ISTANBUL, 2025, 12 (01) : 95 - 102
  • [46] Inflammation, Lymphatics, and Cardiovascular Disease: Amplification by Chronic Kidney Disease
    Kon, Valentina
    Shelton, Elaine L.
    Pitzer, Ashley
    Yang, Hai-Chun
    Kirabo, Annet
    CURRENT HYPERTENSION REPORTS, 2022, 24 (10) : 455 - 463
  • [47] Inflammation, Lymphatics, and Cardiovascular Disease: Amplification by Chronic Kidney Disease
    Valentina Kon
    Elaine L. Shelton
    Ashley Pitzer
    Hai-Chun Yang
    Annet Kirabo
    Current Hypertension Reports, 2022, 24 : 455 - 463
  • [48] Lipid metabolism in chronic kidney disease: The role of statins in cardiovascular risk
    Wanner, Christoph
    Drechsler, Christiane
    Krane, Vera
    JOURNAL OF RENAL NUTRITION, 2007, 17 (01) : 75 - 78
  • [49] DYSLIPIDEMIA IN CHRONIC KIDNEY DISEASE
    Singh, Manish Kumar
    Charan, V. D.
    Parasher, Ishan
    Pankaj, Pranjal
    Kumar, Shrawan
    Gupta, Kusum
    Singh, Vindhyawasini Prasad
    JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS, 2013, 2 (36): : 6864 - 6875
  • [50] Dyslipidemia in Chronic Kidney Disease
    Saland, J.
    Satlin, L.
    Ginsberg, H.
    PEDIATRIC NEPHROLOGY, 2010, 25 (09) : 1960 - 1960